✦ LIBER ✦

P-617 Gefitinib (ZD 1839, Iressa) as a last option for patients with recurrent non-small cell lung cancer (NSCLC)

✍ Scribed by Haringhuizen, Annebeth; Vaessen, Heleen F.R.; Baas, Paul; van Zandwijk, Nico

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-620 Gefitinib (‘Iressa’, ZD1839) monot

✍ Park, Jinny; Park, Byeong-Bae; Lee, Se-Hoon; Park, Se Hoon; Lee, Kyung-Eun; Lee, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Activity of ZD1839 (Gefitinib, Iressa™)

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB

P-612 Gefitinib (Iressa, ZD1839) is acti

✍ Argiris, Athanassios; Mittal, Namrata; Masters, Gregory 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB

New hope for patients with non-small-cel

✍ Glenwood Goss 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 43 KB

P-613 The Israeli experience with gefiti

✍ Gips, M.; Heching, Y.; Levitt, M.; Kuten, A.; Shmueli, E.; Segal, A.; Peretz, T. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB

P-587 Experience from a large multi-cent

✍ van Puijenbroek, R.; Bosquée, L.; Tits, G.; Germonpre, P.; Strobbe, E.; Vansteen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 294 KB